CompletedNCT01192867
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 121 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: December 11, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 629
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT01192867
- Official title
Show the full official title
A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Anaheim, United States · Cerritos, United States
89 more locations
- Downey, United States
- La Palma, United States
- Pasadena, United States
- Pico Rivera, United States
- Miami, United States
- Marietta, United States
- Oak Brook, United States
- Iowa City, United States
- Glen Burnie, United States
- St Louis, United States
- Toms River, United States
- Willingboro, United States
- Albuquerque, United States
- Brooklyn, United States
- Fresh Meadows, United States
- Raleigh, United States
- Cincinnati, United States
- Philadelphia, United States
- Bellaire, United States
- Dallas, United States
- The Woodlands, United States
- Bothell, United States
- Kirkland, United States
- Buenos Aires, Argentina
- CABA, Argentina
- Ciudad Autonoma Bs As, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Santiago del Estero, Argentina
- Westmead, Australia
- Clayton, Australia
- Frankston, Australia
- Melbourne, Australia
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Kuopio, Finland
- Caen, France
- Clermont-Ferrand, France
- Dole, France
- Élancourt, France
- Marseille, France
- Strasbourg, France
- Toulon, France
- Balassagyarmat, Hungary
- Budapest, Hungary
- Győr, Hungary
- Gyula, Hungary
- Ahmedabad, India
- Jaipur, India
- Kalyān, India
- Mangalore, India
- Pune, India
- Vadodara, India
- México, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Arad, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Lasi, Romania
- Oradea, Romania
- Sibiu, Romania
- Targouiste, Romania
- Kemerovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Moscow Region, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Sartatov, Russia
- Talagi, Russia
- Tomsk, Russia
- Busan, South Korea
- Gwangju, South Korea
- Gyeonggi-do, South Korea
- Incheon, South Korea
- Jeollabuk-do, South Korea
- Seoul, South Korea
- Malmö, Sweden
- Stockholm, Sweden
- Uppsala, Sweden
- Edinburgh, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Placebo, RO4917838 and Antipshychotics (Standard of Care).
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia